Dapagliflozin for heart function in acute heart failure
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a medicine called dapagliflozin can improve heart function in people hospitalized with acute heart failure. It may help the heart pump more efficiently and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are in the hospital for acute heart failure and are stable enough to join within 14 days of admission.
- Your kidney function is adequate (eGFR greater than 25).
- You are not currently on dialysis.
- You have not taken any SGLT2 inhibitor (like dapagliflozin) before.
- You do not have type 1 diabetes or a recent history of diabetic ketoacidosis.
- Your blood pressure is not too low (systolic at least 90 mmHg) and you do not need IV medications to support your blood pressure.
- You do not have atrial fibrillation or certain serious heart rhythm problems.
- You do not have severe heart valve disease or other serious heart conditions.
- You are not pregnant, breastfeeding, or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
This trial tests a medicine (a gliflozin) given in the emergency department to older patients with worsening heart failure. It aims to see if early treatment can help them feel better and avoid complications.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
This study tests whether a medicine called dapagliflozin (usually used for diabetes) can reduce heart tissue changes in people with persistent atrial fibrillation. It is given along with the standard ablation procedure, aiming to improve the heart's electrical health and potentially make the procedure more effective.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
Hear when a new Congestive Heart Failure Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.